Treatment of Pulmonary Arterial Hypertension
Top Cited Papers
- 30 September 2004
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (14) , 1425-1436
- https://doi.org/10.1056/nejmra040291
Abstract
Pulmonary arterial hypertension, which is characterized by vascular proliferation and remodeling of small pulmonary vessels, leads to a progressive increase in pulmonary vascular resistance and, ultimately, to right ventricular failure and death. Despite recent major improvements in therapy, no current treatments cure this devastating condition. This article discusses recent progress in developing treatments that prolong patients' lives and improve their quality of life.This publication has 91 references indexed in Scilit:
- RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSIONPublished by Elsevier ,2005
- Clinical classification of pulmonary hypertensionPublished by Elsevier ,2004
- Cellular and molecular pathobiology of pulmonary arterial hypertensionJournal of the American College of Cardiology, 2004
- Primary pulmonary hypertensionThe Lancet, 2003
- Therapy of Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertensionJournal of the American College of Cardiology, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996